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performance status 2 was evident in 26.3 %, 26 %, and 5 % respec-
tively. Among all the patients treated the overall response rate (RR) was 
53.2%, 95% conﬁdence interval 40.1-66%. Response rates were 52.6% 
for arm A, 65.2% for arm B, and 40% for arm C.
The median survival times were as follows: Arm A, 9.8 months, arm 
B, 12 months, arm C, 9.2 months. Survival did not differ among the 3 
arms (p=0.42). The one year survival rate was 26.3 %, 34.7 % and 25% 
in groups A, B and C respectively. Survival for two years or more was 
evident in 10.5%, 17.3%, and 5% in group A, B, and C respectively. 
The median time to progression was 5 months for arm A, 11 months for 
arm B and 6.3 months for arm C. The median number of cycles was 4 
with range 1-6 cycles.
In general, the 3 regimens were well tolerated: Neutropenia (all grades) 
was encountered in 31.5 %, 47.7 %, and 15 %, thrombocytopenia was 
encountered in 5.2 %, 26 % and 5 % and anemia occurred in 31.5 
%, 34.8 % and 35 % in groups A, B and C respectively. As for non 
hematological toxicity, arm A and C had more tendency to neuropathy 
while arm B had tendency to hepatotoxicity but there were no statistical 
differences.
Conclusion: Our results showed that paclitaxel/cisplatin, gemcitabine/
cisplatin, and paclitaxel/gemcitabine combinations provide no signiﬁ-
cant difference in response, survival or toxicity. Treatment was well 
tolerated by the patients in the 3 different groups.
P2-177 NSCLC: Combined Modality Therapy Posters, Tue, Sept 4 
A multicenter phase II study of carboplatin plus gemcitabine 
followed by concomitant chemoradiation in patients with non-
resectable stage III non-small-cell-lung cancer: preliminary report 
of the Cher@Nos trial
Germonpré, Paul R.1 Janssens, Annelies2 Van Moorter, Lut3 Verresen, 
Dirk4 Galdermans, Danny5 Devogelaere, Roger6 Ottevaere, Hugo7 
Mentens, Yves8 De Pooter, Christel4 Goor, Chris5 
1 University Hospital Antwerp, Antwerp, Belgium 2 University Hospital 
Antwerp, Edegem, Belgium 3 Algemeen Stedelijk Ziekenhuis, Aalst, 
Belgium 4 Sint Augustinus, Wilrijk, Belgium 5 ZNA Middelheim, Wilrijk, 
Belgium 6 AZ Damiaan, Oostende, Belgium 7 Aurora Ziekenhuis, Oude-
naarde, Belgium 8 Sint Elisabeth Ziekenhuis, Herentals, Belgium 
Background: Combined chemoradiotherapy is now considered the 
standard of care in patients with unresectable stage III NSCLC. Despite 
the therapeutic advances that have been made during the last decenni-
um, there remains a need for better local and distal control of disease in 
patients with locally advanced NSCLC. At present it is not clear which 
combined modality approach provides optimal results (both in terms of 
survival and toxicity). 
In the present study we wanted to evaluate whether by combining a 
carboplatin-gemcitabine based induction chemotherapy with weekly 
cisplatin during standard thoracic radiotherapy, it is possible to obtain 
good efﬁcacy with minimal toxicity
Methods: Patients (PS 0-1) with unresectable stage III NSCLC were 
treated with 3 cycles of induction chemotherapy followed by chemo-ra-
diotherapy. The induction chemotherapy consisted of carboplatin (AUC 
5 on day 1) with gemcitabine (1200 mg/m2 on day 1 and 8) every 3 
weeks for 3 cycles. The chemo-radiotherapy consisted of cisplatin (30 
mg/m2 weekly) concomitant with conventional radiotherapy (2.0 Gy/
fraction, 5 fractions a week, up to a total dose of 60 Gy). The primary 
endpoint of this phase II trial was a survival rate at 2 years of >35%.
Results: Between February 2003 and November 2005, 45 patients 
were enrolled: The demographics were as follows: 34/11 male/female, 
14/30 stage IIIA/IIIB, median age 62 y (range 41-81 y), 42% squamous 
cell and 33% adenocarcinoma. All patients received at least one cycle 
of induction chemotherapy: 7% only 1 cycle, 7% 2 cycles and 87% all 
3 cycles. Chemoradiotherapy was started in 36 patients. Median total 
radiation dose and duration was 60 Gy and 43 days.
Grade 3/4 toxicities during chemotherapy were: neutropenia (36%), 
thrombocytopenia (18%), febrile neutropenia (1%), rash (1%), eleva-
tion of transaminases (1%) and constipation (1%). The effect of the 









Mean FEV1 (L) 2.26 2.42 2.48 2.33 2.27
Mean FVC (L) 3.19 3.41 3.14 3.32 3.05
Mean DLCO (%) 67.7 60.4 60.7 64.2 65.4
The overall response rate was 31% (2% CR, 29% PR) following induc-
tion chemotherapy, and 58% (2% CR, 56% PR) at the end of treatment. 
With a median follow-up of 14.4 months (range 1-35 months), the 
median progression-free survival is 10.6 months. The overall 1- and 
2-year survivals are 61% and 39%. 
Conclusions: The preliminary results from this phase II trial showed 
that induction chemotherapy with carboplatin and gemcitabine fol-
lowed by thoracic radiotherapy with concurrent weekly cisplatin is a 
well tolerated combined modality approach with promising overall 
survival in patients with unresectable stage III NSCLC.
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Involvement of N2 lymphatic structures, i.e. ipsilateral mediastinal 
lymph nodes in non-small cell cancer of the lung represents a very 
inhomogeneous disease, according to size, number, location, extension, 
and biologic features. Despite recent advances, the therapeutic strategy 
for stage IIIA subcategory remains unclear, particularly regarding the 
role of surgical resection. Controversial recent data suggest a potential 
impact of post-induction surgery speciﬁcally limited to patients who 
respond at the mediastinal level. Others make differences in approaches 
according to the location of mediastinal N2 involvement. Authors 
propose a simple decision-making algorithm based upon last advances 
in imaging, clinical trials, mediastinal status, response after induction, 
staging and re-staging new techniques, and current burning remaining 
questions. 
